Lenalidomide With or Without Ixazomib Citrate and Dexamethasone in Treating Patients With Residual Multiple Myeloma After Donor Stem Cell Transplant
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02389517|
Recruitment Status : Recruiting
First Posted : March 17, 2015
Last Update Posted : May 1, 2019
|Condition or disease||Intervention/treatment||Phase|
|Plasma Cell Myeloma Residual Disease||Drug: Ixazomib Citrate Drug: Lenalidomide Drug: Dexamethasone||Phase 2|
I. To determine the rate of minimal residual disease (MRD)-negative disease by multiparameter-flow cytometry at 12 months after randomization.
I. Evidence of response as demonstrated by the improvement of the depth of response by at least one category according to International Myeloma Working Group (IMWG) response criteria.
II. Progression free survival (PFS). III. Overall survival (OS). IV. Duration of MRD-negative disease. V. Safety and tolerability of experimental arm (ixazomib citrate, lenalidomide, and low dose dexamethasone [IRd]) vs. control arm (lenalidomide [Rd]).
I. Determination of markers of response based on pre-treatment characteristics using methods described in correlative research.
II. Evaluation of MRD by gene sequencing method using the Sequenta platform (LymphoSIGHT®) in parallel with multi-parameter flow cytometry (MFC).
OUTLINE: Patients are randomized to 1 of 2 treatment arms.
ARM I: Patients receive ixazomib citrate orally (PO) on days 1, 8, and 15, lenalidomide PO once daily (QD) on days 1-21, and dexamethasone PO on days 1, 8, 15, and 22 (of courses 1-4 only).
ARM II: Patients receive lenalidomide PO as in Arm I.
In both arms, treatment repeats every 28 days for 12 courses in the absence of disease progression or unacceptable toxicity.
After the completion of treatment, patients are followed up at 30 days and then every 3 months for 2 years.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||86 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Phase II Randomized Trial of Continuation of Post-Transplant Maintenance With Single-Agent Lenalidomide vs. Consolidation/Maintenance With Ixazomib-Lenalidomide-Dexamethasone in Patients With Residual Myeloma|
|Actual Study Start Date :||March 2, 2015|
|Estimated Primary Completion Date :||March 2, 2020|
|Estimated Study Completion Date :||March 2, 2022|
Experimental: Arm I (ixazomib citrate, lenalidomide, dexamethasone)
Patients receive ixazomib citrate PO on days 1, 8, and 15, lenalidomide PO QD on days 1-21, and dexamethasone PO on days 1, 8, 15, and 22 (of courses 1-4 only).
Drug: Ixazomib Citrate
Other Name: DM
Active Comparator: Arm II (lenalidomide)
Patients receive lenalidomide PO as in Arm I.
- Rate of MRD between the two arms, as measured by flow cytometry and sequencing [ Time Frame: At 12 months ]The comparison will be made using a one sided test at the 10% significance level. This comparison will be performed using a Cochran Mantel-Haenszel (CMH) test stratified by very good partial response (VGPR) status and risk factors vs. no risk factors.
- Overall response rate defined as an improvement from very good partial response (VGPR) to near complete response (nCR) or better than nCR including conversion from complete response (CR) to MRD negative disease according to IMWG criteria [ Time Frame: At 6 months ]The rate of overall response will be reported along with its exact 95% binomial confidence interval.
- Overall response defined as an improvement from VGPR to nCR or better than nCR including conversion from CR to MRD negative disease according to IMWG criteria [ Time Frame: At 12 months ]The rate of overall response will be reported along with its exact 95% binomial confidence interval.
- Duration of response (MRD-negative disease) [ Time Frame: From the date of the clinical examination, which confirmed the response, until the date of disease progression, or censoring at the date of last clinical follow-up, assessed up to 2 years ]Duration of response will be assessed conditionally upon achieving at least a partial response.
- Time to progression [ Time Frame: Up to 2 years ]Time to event will be estimated using the product-limit method of Kaplan and Meier.
- Estimated PFS [ Time Frame: From the date of randomization until the date of documented disease progression or death, assessed up to 2 years ]Time to event will be estimated using the product-limit method of Kaplan and Meier. MRD status will be correlated with PFS.
- Estimated OS [ Time Frame: Up to 2 years ]Time to event will be estimated using the product-limit method of Kaplan and Meier.
- Incidence, intensity, and type of adverse events as graded by the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0 [ Time Frame: Up to 30 days post-treatment ]Safety variables will be tabulated and presented for all patients in the study. Exposure to study drug and reasons for discontinuation of study treatment will be tabulated. Group comparisons will be performed using chi-square or Fisher's exact test.
- Markers of response [ Time Frame: Baseline ]Correlative biomarkers will be assessed for association with response in the experimental arm using nonparametric tests given the relatively small number of responders anticipated (20%). A Wilcoxon rank-sum test will be used to compare baseline (pre-treatment) biomarker levels in the responders vs. non-responders.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02389517
|United States, Illinois|
|University of Chicago||Recruiting|
|Chicago, Illinois, United States, 60637|
|Contact: Andrzej J. Jakubowiak 773-834-1592 firstname.lastname@example.org|
|Principal Investigator: Andrzej J. Jakubowiak|
|Principal Investigator:||Andrzej Jakubowiak||University of Chicago|